Pharmaceutical T-Cell Therapy Supply Chain Transformation Case Study

Case studies

SCP

Pharmaceutical T-Cell Therapy Supply Chain Transformation Case Study

Case study of a US pharmaceutical company replacing Excel with Kinaxis RapidResponse to manage personalized T-cell therapy supply chains across global manufacturing and clinical sites.

Published

June 4, 2026

Read time

3 min read

Source

Kinaxis

This case study examines how a US-based cell therapy company scaled from local clinical trials to international operations. The firm replaced manual Excel planning with Kinaxis RapidResponse to coordinate patient-specific material flows, certified apheresis sites, and multi-site manufacturing. The implementation progressed from materials planning through S&OP and MRP, enabling real-time risk assessment and cross-functional decision making while maintaining strict chain-of-custody requirements.

Key takeaways

Phased rollout from Excel to RapidResponse reduced planning cycle times and improved forecast accuracy for patient-specific therapies.

Concurrent planning capabilities supported complex if-then scenario modeling across certified sites and global markets.

End-to-end visibility enabled proactive expiry risk communication for critical treatment components.

Bottom-up prototyping empowered planners to validate solutions before enterprise-wide deployment.

Integration with SAP ERP replaced Oracle systems to align teams during international expansion.

Market overview

SCR methodology note

Vendor landscape

Leaders

Implementation considerations

Important consideration

Original Source

Vendors mentioned in this report

No items found.